Zealand Pharma A/S announced a corporate restructuring intended to leverage its peptide platform by prioritizing investment in its research and development pipeline programs and streamline its commercial operations. The changes will refocus the company's resources reducing expenses while investing in strategic development and commercialization partnerships of pipeline assets. Dr. Adam Steensberg will replace Emmanuel Dulac as Chief Executive Officer of Zealand as of 30 March 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
892.5 DKK | +2.65% |
|
+16.29% | +139.15% |
06-28 | Would you like some more inflation? | ![]() |
06-26 | Zealand Pharma Upsizes Directed Share Offering to $1 Billion Amid Strong Demand | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+139.15% | 9.06B | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- ZEAL Stock
- News Zealand Pharma A/S
- Zealand Pharma Announces CEO Changes